Sheldon Kong, Ph.D. is currently Executive Director and Department Head, Health Economics and Outcomes Research (HEOR) and Value Evidence at Novo Nordisk Inc. in Plainsboro, New Jersey. His team develops HEOR and Real World Evidence strategies, plans and programs; manages research collaboration partnerships with payers, organized providers and academic centers; and generates, interprets and communicates health economic and real world evidence in the United States. Prior to joining Novo Nordisk, he was the Department Head of Global Health Outcomes at Merck leading a team to develop strategy and evidence to support the global value proposition of its pharmaceuticals and vaccines. He was Assistant Professor of Pharmacy Administration at the University of Illinois at Chicago where he taught graduate level Pharmacoeconomics and Advanced Research Methods before joining the pharmaceutical industry and today still holds the appointment of Adjunct Professor of Pharmacy Systems, Outcomes and Policy. He also holds the appointment of Adjunct Professor and Corporate HEOR Advisory Board member at the Rutgers University Ernest Mario School of Pharmacy.